Insucomb is an oral combination hypoglycemic drug. Metformin refers to the biguanides group and decreases the content of both basal and postprandial glucose in blood plasma. Metformin does not initiate insulin secretion hence it does not induce hypoglycemia. It has 3 modes of action that are in: decreasing glucose production by liver through inhibition of gluconeogenesis and glycogenolysis; increasing sensitivity of peripheral receptors to insulin, absorption and utilization of glucose by muscles cells; retaining glucose absorbtion from gastro-intestinal tract (GIT). Also Metformin acts positively on lipid composition of blood, with decreasing total cholesterol level, LDL and TG. Glibenclamide refers to the group of sulfonylurea derivatives II generation. Promotion of insulin secretion by β-cells of pancreatic glands results in decrease of glucose content during treatment with Glibenclamide. Metformin and Glibenclamide have different modes of action but mutually supplement their hypoglycemic activity. Combination of two hypoglycemic drugs has synergetic effect regarding decrease of glucose content.
Insucomb
Metformin+Glibenclamide 500mg/2.5mg Tablets №30
Insucomb
Metformin+Glibenclamide 500mg/5mg Tablets №30